Ventricular Tachycardia

Arrhythmia Mechanisms Revealed by Ripple Mapping

The introduction of cardiac electroanatomic mapping systems in the mid-1990s has permitted investigators to record intracardiac electrograms (EGMs) with accurate spatial localisation in 3D.1 These 3D mapping systems have enabled the display of the cardiac chambers as an anatomical shell upon which voltage, or activation, information can be displayed. Most commonly, colour is used to represent the variation of a single parameter that has been derived from the EGM at each sampled location.

Arrhythmogenic Inflammatory Cardiomyopathy: A Review

Ventricular arrhythmias (VA) are commonly associated with structural heart disease and have substantial impact on patient outcomes and health system costs. Within the realm of cardiomyopathy (CM), there has been substantial progress with respect to ischaemic CM (ICM) in the understanding of infarct related scar biology and scar-mediated ventricular tachycardia (VT).

Practical Guide to Ablation for Epicardial Ventricular Tachycardia: When to Get Access, How to Deal with Anticoagulation and How to Prevent Complications

Ventricular tachycardia (VT) is one of the most challenging medical conditions faced by cardiac patients and physicians treating them. Antiarrhythmic medications have limited effectiveness and are frequently poorly tolerated.1–4 Catheter ablation is increasingly used to treat patients successfully.1,5–7 Most VTs can be ablated endocardially but some require epicardial mapping and ablation.

Non-invasive Cardiac Radiation for Ablation of Ventricular Tachycardia: a New Therapeutic Paradigm in Electrophysiology

Myocardial scars from infarction or replacement fibrosis in non-ischaemic cardiomyopathies are the common substrate for sustained monomorphic ventricular tachycardia (VT).1,2 In selected patients at high risk of ventricular arrhythmias, placement of an implantable cardioverter-defibrillator (ICD) is effective for prevention of sudden cardiac death.2 Although ICDs are effective in terminating VT and preventing sudden cardiac death, shocks from ICDs reduce quality of life, and multiple

Limitations and Challenges in Mapping Ventricular Tachycardia: New Technologies and Future Directions

Recurrent episodes of ventricular tachycardia (VT) in patients with structural heart disease are associated with increased mortality and morbidity, despite the life-saving benefits of implantable cardiac defibrillators (ICDs).1,2 Because ICD therapies are abortive and do not alter the underlying arrhythmogenic substrate, their reduction becomes important, especially as recurrent shocks can cause increased myocardial damage and stunning, despite the conversion of VT/VF.3,4 Antiarrhythmic drugs can reduce the number of ICD therapies, but their long-term